Welcome to our dedicated page for Johnson & Johnson SEC filings (Ticker: JNJ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Johnson & Johnson (NYSE: JNJ) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a large New Jersey–incorporated healthcare issuer with common stock and multiple series of notes listed on the New York Stock Exchange, Johnson & Johnson reports material events, financial results and capital structure details through forms such as 10-K, 10-Q and 8-K.
Recent Form 8-K filings illustrate how Johnson & Johnson uses current reports to communicate key developments. For example, the company has filed 8-Ks to announce quarterly sales and earnings results for specific fiscal quarters, and to disclose its intent to separate its Orthopaedics business. These filings also list the securities registered under Section 12(b) of the Exchange Act, including the JNJ common stock and various notes with maturities extending from the late 2020s through the 2050s, each with its own NYSE trading symbol.
On this page, users can review Johnson & Johnson’s periodic reports for detailed information on its Innovative Medicine and MedTech operations, risk factors, research and development spending, and manufacturing and investment plans. Annual reports on Form 10-K and quarterly reports on Form 10-Q provide management’s discussion and analysis, segment information and notes to the financial statements, while current reports on Form 8-K highlight specific corporate actions, clinical or regulatory milestones and financing activities as they occur.
Stock Titan enhances these filings with AI-powered summaries that explain the key points of lengthy documents, helping readers quickly understand topics such as revenue drivers, major therapeutic areas, MedTech initiatives, capital allocation decisions and announced business changes like the planned Orthopaedics separation. The platform also surfaces relevant items related to Johnson & Johnson’s registered debt securities and any disclosed board or governance actions. For investors, analysts and researchers, this page offers a structured view of Johnson & Johnson’s regulatory record, with real-time updates as new filings are posted to EDGAR.
Johnson & Johnson director reports deferred share units award
A Johnson & Johnson (JNJ) director reported receiving 185.533 Deferred Share Units (DSUs) on 12/09/2025 at a price of $202.12 per unit. After this transaction, the director beneficially owns 5,058.0682 DSUs in total, held directly.
The DSUs were acquired by deferring the director’s cash retainer under Johnson & Johnson’s Amended and Restated Deferred Fee Plan for Directors. These units will be settled in cash when the director’s board service ends, and each DSU represents the fair market value of one share of Johnson & Johnson common stock on the business day before settlement. The total includes dividend-equivalent rights that accrue on DSUs in line with the company’s quarterly dividend.
Johnson & Johnson director reports deferred share unit award
A Johnson & Johnson (JNJ) director reported receiving 247.378 Deferred Share Units (DSUs) on 12/09/2025 at a price of $202.12 per unit under the company’s Amended and Restated Deferred Fee Plan for Directors. After this transaction, the director beneficially owned 14,153.1187 DSUs in total.
The DSUs represent the fair market value of one share of Johnson & Johnson common stock and are to be settled in cash when the director’s service on the board ends. The holdings also include dividend equivalent rights that accrue on DSUs in line with the company’s quarterly dividend, keeping the director’s deferred compensation aligned with shareholder payouts.
Johnson & Johnson director Daniel E. Pinto reported a compensation-related equity transaction. On 12/09/2025, he acquired 154.611 Deferred Share Units (DSUs) under Johnson & Johnson’s Amended and Restated Deferred Fee Plan for Directors at a derivative security price of $202.12. Following this transaction, he beneficially owned 331.233 DSUs.
The DSUs represent deferred cash retainers and are to be settled in cash when his service as a director ends. Each DSU is tied to the fair market value of one share of Johnson & Johnson common stock on the business day before settlement. The reported balance also includes dividend equivalent rights accrued on DSUs he already held.
Johnson & Johnson director John Morikis reported buying company stock. On 11/26/2025, he acquired 1,250 shares of common stock at a price of $206.15 per share, coded as transaction type "P." After this purchase, he beneficially owned 1,848.51 shares, held directly. The Form 4 indicates the filing relates to one reporting person and shows no derivative securities transactions.
Johnson & Johnson filed a Form 4 reporting small open-market sales of CVRx, Inc. common stock held indirectly through its subsidiary Johnson & Johnson Innovation - JJDC, Inc. JJDC sold 500 CVRx shares on 11/21/2025 at a price of $10.00 per share and 2,200 shares on 11/24/2025 at a weighted average price of $10.06 per share. After these transactions, Johnson & Johnson, through JJDC, indirectly beneficially owned 4,047,198 CVRx common shares. The filing notes that the 11/24/2025 price reflects multiple trades between $10.00 and $10.10, and Johnson & Johnson undertakes to provide detailed trade breakdowns upon request.
Johnson & Johnson filed a Form 13F reporting institutional holdings on behalf of its investment manager. The report lists 20 holdings with a total reported market value of
Johnson & Johnson filed a Form 4 reporting open‑market sales of CVRx (CVRX)52,332 shares at a weighted average price of $10.21 on 11/06/2025 and 200 shares at $10.00 on 11/07/2025. After these transactions, J&J indirectly beneficially owned 4,050,898 CVRx shares through JJDC. Prices for the 11/06 trades ranged from $10.00 to $10.49 per share.
Johnson & Johnson reported significantly stronger results for the quarter and first nine months of 2025. Quarterly sales rose to $23.99 billion, up 6.8% from a year ago, with net earnings climbing to $5.15 billion versus $2.69 billion. Diluted EPS increased to $2.12 from $1.11.
For the first nine months, sales reached $69.63 billion, up 5.0%, while net earnings more than doubled to $21.69 billion, and diluted EPS rose to $8.94 from $4.38. Results benefited from a roughly $7 billion reversal of previously accrued talc reserves, partly offset by a higher effective tax rate of 21.5% following U.S. tax law changes.
The company closed the $14.5 billion acquisition of Intra-Cellular Therapies, adding CAPLYTA and a CNS pipeline to the Innovative Medicine segment. MedTech growth was supported by prior acquisitions such as Shockwave. As of October 17, 2025, there were 2,409,295,102 common shares outstanding.
Johnson & Johnson (JNJ) insider trade: EVP, Innovative Medicine, R&D, John C. Reed exercised 21,721 employee stock options at $157.92 per share and sold 21,721 common shares at a weighted average price of $192.7072 on 10/17/2025. Following these transactions, he directly beneficially owned 10,658 common shares and held 43,442 derivative securities (options). The sale price reflects multiple trades between $192.69 and $192.87.
Johnson & Johnson (JNJ) filed a Form 144 notice covering a proposed sale of 21,721 shares of common stock with an aggregate market value of $4,185,794.26. The filing lists an approximate sale date of 10/17/2025 on the NYSE through Fidelity Brokerage Services LLC.
The securities were acquired on 10/17/2025 via an option granted on 02/15/2024, with payment made on 10/17/2025 in cash. The notice states 2,408,338,872 shares outstanding. Over the past three months, John C. Reed sold 19,137 shares on 07/17/2025 for gross proceeds of $3,129,830.51.